1
|
Lindemann M, Moldovan RP, Hinz S, Deuther-Conrad W, Gündel D, Dukic-Stefanovic S, Toussaint M, Teodoro R, Juhl C, Steinbach J, Brust P, Müller CE, Wenzel B. Development of a Radiofluorinated Adenosine A 2B Receptor Antagonist as Potential Ligand for PET Imaging. Int J Mol Sci 2020; 21:ijms21093197. [PMID: 32366046 PMCID: PMC7246765 DOI: 10.3390/ijms21093197] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/06/2020] [Revised: 04/28/2020] [Accepted: 04/28/2020] [Indexed: 01/22/2023] Open
Abstract
The adenosine A2B receptor has been proposed as a novel therapeutic target in cancer, as its expression is drastically elevated in several tumors and cancer cells. Noninvasive molecular imaging via positron emission tomography (PET) would allow the in vivo quantification of this receptor in pathological processes and most likely enable the identification and clinical monitoring of respective cancer therapies. On the basis of a bicyclic pyridopyrimidine-2,4-dione core structure, the new adenosine A2B receptor ligand 9 was synthesized, containing a 2-fluoropyridine moiety suitable for labeling with the short-lived PET radionuclide fluorine-18. Compound 9 showed a high binding affinity for the human A2B receptor (Ki(A2B) = 2.51 nM), along with high selectivities versus the A1, A2A, and A3 receptor subtypes. Therefore, it was radiofluorinated via nucleophilic aromatic substitution of the corresponding nitro precursor using [18F]F-/K2.2.2./K2CO3 in DMSO at 120 °C. Metabolic studies of [18F]9 in mice revealed about 60% of radiotracer intact in plasma at 30 minutes p.i. A preliminary PET study in healthy mice showed an overall biodistribution of [18F]9, corresponding to the known ubiquitous but low expression of the A2B receptor. Consequently, [18F]9 represents a novel PET radiotracer with high affinity and selectivity toward the adenosine A2B receptor and a suitable in vivo profile. Subsequent studies are envisaged to investigate the applicability of [18F]9 to detect alterations in the receptor density in certain cancer-related disease models.
Collapse
Affiliation(s)
- Marcel Lindemann
- Department of Neuroradiopharmaceuticals, Institute of Radiopharmaceutical Cancer Research, Helmholtz-Zentrum Dresden-Rossendorf, 04318 Leipzig, Germany; (M.L.); (R.-P.M.); (W.D.-C.); (D.G.); (S.D.-S.); (M.T.); (R.T.); (J.S.); (P.B.)
| | - Rareş-Petru Moldovan
- Department of Neuroradiopharmaceuticals, Institute of Radiopharmaceutical Cancer Research, Helmholtz-Zentrum Dresden-Rossendorf, 04318 Leipzig, Germany; (M.L.); (R.-P.M.); (W.D.-C.); (D.G.); (S.D.-S.); (M.T.); (R.T.); (J.S.); (P.B.)
| | - Sonja Hinz
- Pharma Center Bonn, Pharmaceutical & Medicinal Chemistry, Pharmaceutical Institute, University of Bonn, 53121 Bonn, Germany; (S.H.); (C.E.M.)
| | - Winnie Deuther-Conrad
- Department of Neuroradiopharmaceuticals, Institute of Radiopharmaceutical Cancer Research, Helmholtz-Zentrum Dresden-Rossendorf, 04318 Leipzig, Germany; (M.L.); (R.-P.M.); (W.D.-C.); (D.G.); (S.D.-S.); (M.T.); (R.T.); (J.S.); (P.B.)
| | - Daniel Gündel
- Department of Neuroradiopharmaceuticals, Institute of Radiopharmaceutical Cancer Research, Helmholtz-Zentrum Dresden-Rossendorf, 04318 Leipzig, Germany; (M.L.); (R.-P.M.); (W.D.-C.); (D.G.); (S.D.-S.); (M.T.); (R.T.); (J.S.); (P.B.)
| | - Sladjana Dukic-Stefanovic
- Department of Neuroradiopharmaceuticals, Institute of Radiopharmaceutical Cancer Research, Helmholtz-Zentrum Dresden-Rossendorf, 04318 Leipzig, Germany; (M.L.); (R.-P.M.); (W.D.-C.); (D.G.); (S.D.-S.); (M.T.); (R.T.); (J.S.); (P.B.)
- ROTOP Pharmaka GmbH, 01328 Dresden, Germany;
| | - Magali Toussaint
- Department of Neuroradiopharmaceuticals, Institute of Radiopharmaceutical Cancer Research, Helmholtz-Zentrum Dresden-Rossendorf, 04318 Leipzig, Germany; (M.L.); (R.-P.M.); (W.D.-C.); (D.G.); (S.D.-S.); (M.T.); (R.T.); (J.S.); (P.B.)
| | - Rodrigo Teodoro
- Department of Neuroradiopharmaceuticals, Institute of Radiopharmaceutical Cancer Research, Helmholtz-Zentrum Dresden-Rossendorf, 04318 Leipzig, Germany; (M.L.); (R.-P.M.); (W.D.-C.); (D.G.); (S.D.-S.); (M.T.); (R.T.); (J.S.); (P.B.)
| | | | - Jörg Steinbach
- Department of Neuroradiopharmaceuticals, Institute of Radiopharmaceutical Cancer Research, Helmholtz-Zentrum Dresden-Rossendorf, 04318 Leipzig, Germany; (M.L.); (R.-P.M.); (W.D.-C.); (D.G.); (S.D.-S.); (M.T.); (R.T.); (J.S.); (P.B.)
| | - Peter Brust
- Department of Neuroradiopharmaceuticals, Institute of Radiopharmaceutical Cancer Research, Helmholtz-Zentrum Dresden-Rossendorf, 04318 Leipzig, Germany; (M.L.); (R.-P.M.); (W.D.-C.); (D.G.); (S.D.-S.); (M.T.); (R.T.); (J.S.); (P.B.)
| | - Christa E. Müller
- Pharma Center Bonn, Pharmaceutical & Medicinal Chemistry, Pharmaceutical Institute, University of Bonn, 53121 Bonn, Germany; (S.H.); (C.E.M.)
| | - Barbara Wenzel
- Department of Neuroradiopharmaceuticals, Institute of Radiopharmaceutical Cancer Research, Helmholtz-Zentrum Dresden-Rossendorf, 04318 Leipzig, Germany; (M.L.); (R.-P.M.); (W.D.-C.); (D.G.); (S.D.-S.); (M.T.); (R.T.); (J.S.); (P.B.)
- Correspondence: ; Tel.: +49-341-2341794637
| |
Collapse
|
2
|
A 2B Adenosine Receptor and Cancer. Int J Mol Sci 2019; 20:ijms20205139. [PMID: 31627281 PMCID: PMC6829478 DOI: 10.3390/ijms20205139] [Citation(s) in RCA: 56] [Impact Index Per Article: 11.2] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/25/2019] [Revised: 10/11/2019] [Accepted: 10/12/2019] [Indexed: 12/28/2022] Open
Abstract
There are four subtypes of adenosine receptors (ARs), named A1, A2A, A2B and A3, all of which are G protein-coupled receptors (GPCRs). Locally produced adenosine is a suppressant in anti-tumor immune surveillance. The A2BAR, coupled to both Gαs and Gαi G proteins, is one of the several GPCRs that are expressed in a significantly higher level in certain cancer tissues, in comparison to adjacent normal tissues. There is growing evidence that the A2BAR plays an important role in tumor cell proliferation, angiogenesis, metastasis, and immune suppression. Thus, A2BAR antagonists are novel, potentially attractive anticancer agents. Several antagonists targeting A2BAR are currently in clinical trials for various types of cancers. In this review, we first describe the signaling, agonists, and antagonists of the A2BAR. We further discuss the role of the A2BAR in the progression of various cancers, and the rationale of using A2BAR antagonists in cancer therapy.
Collapse
|
3
|
Jiang J, Seel CJ, Temirak A, Namasivayam V, Arridu A, Schabikowski J, Baqi Y, Hinz S, Hockemeyer J, Müller CE. A 2B Adenosine Receptor Antagonists with Picomolar Potency. J Med Chem 2019; 62:4032-4055. [PMID: 30835463 DOI: 10.1021/acs.jmedchem.9b00071] [Citation(s) in RCA: 16] [Impact Index Per Article: 3.2] [Reference Citation Analysis] [Abstract] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/11/2022]
Abstract
The A2B adenosine receptor (A2BAR) was proposed as a novel target for the (immuno)therapy of cancer since A2BAR blockade results in antiproliferative, antiangiogenic, antimetastatic, and immunostimulatory effects. In this study, we explored the structure-activity relationships of xanthin-8-yl-benzenesulfonamides mainly by introducing a variety of linkers and substituents attached to the sulfonamide residue. A new, convergent strategy was established, which facilitated the synthesis of the target compounds. Many of the new compounds exhibited subnanomolar affinity for the A2BAR combined with high selectivity. Functional groups were introduced, which will allow the attachment of dyes and other reporter groups. 8-(4-((4-(4-Bromophenyl)piperazin-1-yl)sulfonyl)phenyl)-1-propylxanthine (34, PSB-1901) was the most potent A2B-antagonist ( Ki 0.0835 nM, KB 0.0598 nM, human A2BAR) with >10 000-fold selectivity versus all other AR subtypes. It was similarly potent and selective at the mouse A2BAR, making it a promising tool for preclinical studies. Computational studies predicted halogen bonding to contribute to the outstanding potency of 34.
Collapse
Affiliation(s)
- Jie Jiang
- Pharmaceutical Chemistry I, PharmaCenter Bonn, Pharmaceutical Institute , Rheinische Friedrich-Wilhelms-Universitat Bonn , An der Immenburg 4 , D-53121 Bonn , Germany
| | - Catharina Julia Seel
- Pharmaceutical Chemistry I, PharmaCenter Bonn, Pharmaceutical Institute , Rheinische Friedrich-Wilhelms-Universitat Bonn , An der Immenburg 4 , D-53121 Bonn , Germany
| | - Ahmed Temirak
- Pharmaceutical Chemistry I, PharmaCenter Bonn, Pharmaceutical Institute , Rheinische Friedrich-Wilhelms-Universitat Bonn , An der Immenburg 4 , D-53121 Bonn , Germany
| | - Vigneshwaran Namasivayam
- Pharmaceutical Chemistry I, PharmaCenter Bonn, Pharmaceutical Institute , Rheinische Friedrich-Wilhelms-Universitat Bonn , An der Immenburg 4 , D-53121 Bonn , Germany
| | - Antonella Arridu
- Pharmaceutical Chemistry I, PharmaCenter Bonn, Pharmaceutical Institute , Rheinische Friedrich-Wilhelms-Universitat Bonn , An der Immenburg 4 , D-53121 Bonn , Germany
| | - Jakub Schabikowski
- Pharmaceutical Chemistry I, PharmaCenter Bonn, Pharmaceutical Institute , Rheinische Friedrich-Wilhelms-Universitat Bonn , An der Immenburg 4 , D-53121 Bonn , Germany
| | - Younis Baqi
- Department of Chemistry, Faculty of Science , Sultan Qaboos University , P.O. Box 36, 123 Muscat , Oman
| | - Sonja Hinz
- Pharmaceutical Chemistry I, PharmaCenter Bonn, Pharmaceutical Institute , Rheinische Friedrich-Wilhelms-Universitat Bonn , An der Immenburg 4 , D-53121 Bonn , Germany
| | - Jörg Hockemeyer
- Pharmaceutical Chemistry I, PharmaCenter Bonn, Pharmaceutical Institute , Rheinische Friedrich-Wilhelms-Universitat Bonn , An der Immenburg 4 , D-53121 Bonn , Germany
| | - Christa E Müller
- Pharmaceutical Chemistry I, PharmaCenter Bonn, Pharmaceutical Institute , Rheinische Friedrich-Wilhelms-Universitat Bonn , An der Immenburg 4 , D-53121 Bonn , Germany
| |
Collapse
|
4
|
Härter M, Kalthof B, Delbeck M, Lustig K, Gerisch M, Schulz S, Kast R, Meibom D, Lindner N. Novel non-xanthine antagonist of the A 2B adenosine receptor: From HTS hit to lead structure. Eur J Med Chem 2018; 163:763-778. [PMID: 30576906 DOI: 10.1016/j.ejmech.2018.11.045] [Citation(s) in RCA: 9] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/27/2018] [Revised: 11/16/2018] [Accepted: 11/19/2018] [Indexed: 11/17/2022]
Abstract
The A2B adenosine receptor is a G protein-coupled receptor that belongs to the four member family of adenosine receptors: A1, A2A, A2B, A3. While adenosine-mediated A2B receptor signaling attenuates acute inflammation, facilitates tissue adaptation to hypoxia, and induces increased ischemia tolerance under conditions of an acute insult, persistently elevated adenosine levels and A2B receptor signaling are characteristics of a number of chronic disease states. In this report we describe the discovery of certain thienouracils (thieno[2,3-d]pyrimidine-2,4(1H,3H)-diones) as antagonists of the A2B adenosine receptor by high-throughput screening from our corporate substance collection. The structure optimization of the initial screening hits led to BAY-545, an A2B receptor antagonist that was suitable for in vivo testing. The structure optimization work, SAR that was derived from there, as well as the properties of BAY-545 are also described. In vivo efficacy of BAY-545 was demonstrated in two models of lung fibrosis and data is presented.
Collapse
Affiliation(s)
- Michael Härter
- Small Molecules Innovation, Research & Development, Bayer Pharmaceuticals, Wuppertal, Germany.
| | - Bernd Kalthof
- Small Molecules Innovation, Research & Development, Bayer Pharmaceuticals, Wuppertal, Germany
| | - Martina Delbeck
- Preclinical Research, Research & Development, Bayer Pharmaceuticals, Wuppertal, Germany
| | - Klemens Lustig
- Translational Sciences, Research & Development, Bayer Pharmaceuticals, Wuppertal, Germany
| | - Michael Gerisch
- Translational Sciences, Research & Development, Bayer Pharmaceuticals, Wuppertal, Germany
| | - Simone Schulz
- Translational Sciences, Research & Development, Bayer Pharmaceuticals, Wuppertal, Germany
| | - Raimund Kast
- Preclinical Research, Research & Development, Bayer Pharmaceuticals, Wuppertal, Germany
| | - Daniel Meibom
- Small Molecules Innovation, Research & Development, Bayer Pharmaceuticals, Wuppertal, Germany
| | - Niels Lindner
- Small Molecules Innovation, Research & Development, Bayer Pharmaceuticals, Wuppertal, Germany
| |
Collapse
|
5
|
Lindemann M, Hinz S, Deuther-Conrad W, Namasivayam V, Dukic-Stefanovic S, Teodoro R, Toussaint M, Kranz M, Juhl C, Steinbach J, Brust P, Müller CE, Wenzel B. Radiosynthesis and in vivo evaluation of a fluorine-18 labeled pyrazine based radioligand for PET imaging of the adenosine A 2B receptor. Bioorg Med Chem 2018; 26:4650-4663. [PMID: 30104122 DOI: 10.1016/j.bmc.2018.07.045] [Citation(s) in RCA: 16] [Impact Index Per Article: 2.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/23/2018] [Revised: 07/23/2018] [Accepted: 07/26/2018] [Indexed: 02/07/2023]
Abstract
On the basis of a pyrazine core structure, three new adenosine A2B receptor ligands (7a-c) were synthesized containing a 2-fluoropyridine moiety suitable for 18F-labeling. Compound 7a was docked into a homology model of the A2B receptor based on X-ray structures of the related A2A receptor, and its interactions with the adenosine binding site were rationalized. Binding affinity data were determined at the four human adenosine receptor subtypes. Despite a rather low selectivity regarding the A1 receptor, 7a was radiolabeled as the most suitable candidate (Ki(A2B) = 4.24 nM) in order to perform in vivo studies in mice with the aim to estimate fundamental pharmacokinetic characteristics of the compound class. Organ distribution studies and a single PET study demonstrated brain uptake of [18F]7a with a standardized uptake value (SUV) of ≈1 at 5 min post injection followed by a fast wash out. Metabolism studies of [18F]7a in mice revealed the formation of a blood-brain barrier penetrable radiometabolite, which could be structurally identified. The results of this study provide an important basis for the design of new derivatives with improved binding properties and metabolic stability in vivo.
Collapse
Affiliation(s)
- Marcel Lindemann
- Helmholtz-Zentrum Dresden-Rossendorf, Institute of Radiopharmaceutical Cancer Research, Department of Neuroradiopharmaceuticals, Leipzig, Germany
| | - Sonja Hinz
- Pharma Center Bonn, Pharmaceutical Institute, Pharmaceutical Chemistry I, University of Bonn, Bonn, Germany
| | - Winnie Deuther-Conrad
- Helmholtz-Zentrum Dresden-Rossendorf, Institute of Radiopharmaceutical Cancer Research, Department of Neuroradiopharmaceuticals, Leipzig, Germany
| | - Vigneshwaran Namasivayam
- Pharma Center Bonn, Pharmaceutical Institute, Pharmaceutical Chemistry I, University of Bonn, Bonn, Germany
| | | | - Rodrigo Teodoro
- Helmholtz-Zentrum Dresden-Rossendorf, Institute of Radiopharmaceutical Cancer Research, Department of Neuroradiopharmaceuticals, Leipzig, Germany
| | - Magali Toussaint
- Helmholtz-Zentrum Dresden-Rossendorf, Institute of Radiopharmaceutical Cancer Research, Department of Neuroradiopharmaceuticals, Leipzig, Germany
| | - Mathias Kranz
- Helmholtz-Zentrum Dresden-Rossendorf, Institute of Radiopharmaceutical Cancer Research, Department of Neuroradiopharmaceuticals, Leipzig, Germany
| | | | - Jörg Steinbach
- Helmholtz-Zentrum Dresden-Rossendorf, Institute of Radiopharmaceutical Cancer Research, Department of Neuroradiopharmaceuticals, Leipzig, Germany
| | - Peter Brust
- Helmholtz-Zentrum Dresden-Rossendorf, Institute of Radiopharmaceutical Cancer Research, Department of Neuroradiopharmaceuticals, Leipzig, Germany
| | - Christa E Müller
- Pharma Center Bonn, Pharmaceutical Institute, Pharmaceutical Chemistry I, University of Bonn, Bonn, Germany
| | - Barbara Wenzel
- Helmholtz-Zentrum Dresden-Rossendorf, Institute of Radiopharmaceutical Cancer Research, Department of Neuroradiopharmaceuticals, Leipzig, Germany.
| |
Collapse
|
6
|
Synthesis and adenosine receptors binding studies of new fluorinated analogues of pyrido[2,3-d]pyrimidines and quinazolines. Med Chem Res 2017. [DOI: 10.1007/s00044-017-2099-z] [Citation(s) in RCA: 22] [Impact Index Per Article: 3.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/27/2022]
|
7
|
Talele TT. The "Cyclopropyl Fragment" is a Versatile Player that Frequently Appears in Preclinical/Clinical Drug Molecules. J Med Chem 2016; 59:8712-8756. [PMID: 27299736 DOI: 10.1021/acs.jmedchem.6b00472] [Citation(s) in RCA: 565] [Impact Index Per Article: 70.6] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/08/2023]
Abstract
Recently, there has been an increasing use of the cyclopropyl ring in drug development to transition drug candidates from the preclinical to clinical stage. Important features of the cyclopropane ring are, the (1) coplanarity of the three carbon atoms, (2) relatively shorter (1.51 Å) C-C bonds, (3) enhanced π-character of C-C bonds, and (4) C-H bonds are shorter and stronger than those in alkanes. The present review will focus on the contributions that a cyclopropyl ring makes to the properties of drugs containing it. Consequently, the cyclopropyl ring addresses multiple roadblocks that can occur during drug discovery such as (a) enhancing potency, (b) reducing off-target effects,
Collapse
Affiliation(s)
- Tanaji T Talele
- Department of Pharmaceutical Sciences, College of Pharmacy and Health Sciences, St. John's University , 8000 Utopia Parkway, Queens, New York 11439, United States
| |
Collapse
|
8
|
El Maatougui A, Azuaje J, González-Gómez M, Miguez G, Crespo A, Carbajales C, Escalante L, García-Mera X, Gutiérrez-de-Terán H, Sotelo E. Discovery of Potent and Highly Selective A2B Adenosine Receptor Antagonist Chemotypes. J Med Chem 2016; 59:1967-83. [DOI: 10.1021/acs.jmedchem.5b01586] [Citation(s) in RCA: 47] [Impact Index Per Article: 5.9] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/28/2023]
|
9
|
Federico S, Redenti S, Sturlese M, Ciancetta A, Kachler S, Klotz KN, Cacciari B, Moro S, Spalluto G. The Influence of the 1-(3-Trifluoromethyl-Benzyl)-1H-Pyrazole-4-yl Moiety on the Adenosine Receptors Affinity Profile of Pyrazolo[4,3-e][1,2,4]Triazolo[1,5-c]Pyrimidine Derivatives. PLoS One 2015; 10:e0143504. [PMID: 26625265 PMCID: PMC4666649 DOI: 10.1371/journal.pone.0143504] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/11/2015] [Accepted: 11/05/2015] [Indexed: 12/03/2022] Open
Abstract
A new series of pyrazolo[4,3-e][1,2,4]triazolo[1,5-c]pyrimidine (PTP) derivatives has been developed in order to explore their affinity and selectivity profile at the four adenosine receptor subtypes. In particular, the PTP scaffold was conjugated at the C2 position with the 1-(3-trifluoromethyl-benzyl)-1H-pyrazole, a group believed to confer potency and selectivity toward the human (h) A2B adenosine receptor (AR) to the xanthine ligand 8-(1-(3-(trifluoromethyl)benzyl)-1H-pyrazol-4-yl)-1,3-dimethyl-1H-purine-2,6(3H,7H)-dione (CVT 6975). Interestingly, the synthesized compounds turned out to be inactive at the hA2B AR but they displayed affinity at the hA3 AR in the nanomolar range. The best compound of the series (6) shows both high affinity (hA3 AR Ki = 11 nM) and selectivity (A1/A3 and A2A/A3 > 9090; A2B/A3 > 909) at the hA3 AR. To better rationalize these results, a molecular docking study on the four AR subtypes was performed for all the synthesized compounds. In addition, CTV 6975 and two close analogues have been subjected to the same molecular docking protocol to investigate the role of the 1-(3-trifluoromethyl-benzyl)-1H-pyrazole on the binding at the four ARs.
Collapse
Affiliation(s)
- Stephanie Federico
- Dipartimento di Scienze Chimiche e Farmaceutiche, Università degli Studi di Trieste, Trieste, Italy
| | - Sara Redenti
- Dipartimento di Scienze Chimiche e Farmaceutiche, Università degli Studi di Trieste, Trieste, Italy
| | - Mattia Sturlese
- Molecular Modeling Section (MMS), Dipartimento di Scienze del Farmaco, Università degli Studi di Padova, Padova, Italy
| | - Antonella Ciancetta
- Molecular Modeling Section (MMS), Dipartimento di Scienze del Farmaco, Università degli Studi di Padova, Padova, Italy
| | - Sonja Kachler
- Institut für Pharmakologie und Toxicologie, Universität Würzburg, Würzburg, Germany
| | - Karl-Norbert Klotz
- Institut für Pharmakologie und Toxicologie, Universität Würzburg, Würzburg, Germany
| | - Barbara Cacciari
- Dipartimento di Scienze Chimiche e Farmaceutiche, Università degli Studi di Ferrara, Ferrara, Italy
| | - Stefano Moro
- Molecular Modeling Section (MMS), Dipartimento di Scienze del Farmaco, Università degli Studi di Padova, Padova, Italy
| | - Giampiero Spalluto
- Dipartimento di Scienze Chimiche e Farmaceutiche, Università degli Studi di Trieste, Trieste, Italy
| |
Collapse
|
10
|
Trincavelli ML, Giacomelli C, Daniele S, Taliani S, Cosimelli B, Laneri S, Severi E, Barresi E, Pugliesi I, Greco G, Novellino E, Da Settimo F, Martini C. Allosteric modulators of human A2B adenosine receptor. Biochim Biophys Acta Gen Subj 2013; 1840:1194-203. [PMID: 24361612 DOI: 10.1016/j.bbagen.2013.12.021] [Citation(s) in RCA: 23] [Impact Index Per Article: 2.1] [Reference Citation Analysis] [Abstract] [Key Words] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/29/2013] [Revised: 11/22/2013] [Accepted: 12/13/2013] [Indexed: 12/20/2022]
Abstract
BACKGROUND Among adenosine receptors (ARs) the A2B subtype exhibits low affinity for the endogenous agonist compared with the A1, A2A, and A3 subtypes and is therefore activated when concentrations of adenosine increase to a large extent following tissue damages (e.g. ischemia, inflammation). For this reason, A2B AR represents an important pharmacological target. METHODS We evaluated seven 1-benzyl-3-ketoindole derivatives (7-9) for their ability to act as positive or negative allosteric modulators of human A2B AR through binding and functional assays using CHO cells expressing human A1, A2A, A2B, and A3 ARs. RESULTS The investigated compounds behaved as specific positive or negative allosteric modulators of human A2B AR depending on small differences in their structures. The positive allosteric modulators 7a,b and 8a increased agonist efficacy without any effect on agonist potency. The negative allosteric modulators 8b,c and 9a,b reduced agonist potency and efficacy. CONCLUSIONS A number of 1-benzyl-3-ketoindole derivatives were pharmacologically characterized as selective positive (7a,b) or negative (8c, 9a,b) allosteric modulators of human A2B AR. GENERAL SIGNIFICANCE The 1-benzyl-3-ketoindole derivatives 7-9 acting as positive or negative allosteric modulators of human A2B AR represent new pharmacological tools useful for the development of therapeutic agents to treat pathological conditions related to an altered functionality of A2B AR.
Collapse
Affiliation(s)
| | - Chiara Giacomelli
- Dipartimento di Farmacia, Università di Pisa, Via Bonanno Pisano 6, 56126 Pisa, Italy
| | - Simona Daniele
- Dipartimento di Farmacia, Università di Pisa, Via Bonanno Pisano 6, 56126 Pisa, Italy
| | - Sabrina Taliani
- Dipartimento di Farmacia, Università di Pisa, Via Bonanno Pisano 6, 56126 Pisa, Italy
| | - Barbara Cosimelli
- Dipartimento di Farmacia, Università di Napoli Federico II, Via Domenico Montesano 49, 80131 Napoli, Italy.
| | - Sonia Laneri
- Dipartimento di Farmacia, Università di Napoli Federico II, Via Domenico Montesano 49, 80131 Napoli, Italy
| | - Elda Severi
- Dipartimento di Farmacia, Università di Napoli Federico II, Via Domenico Montesano 49, 80131 Napoli, Italy
| | - Elisabetta Barresi
- Dipartimento di Farmacia, Università di Pisa, Via Bonanno Pisano 6, 56126 Pisa, Italy
| | - Isabella Pugliesi
- Dipartimento di Farmacia, Università di Pisa, Via Bonanno Pisano 6, 56126 Pisa, Italy
| | - Giovanni Greco
- Dipartimento di Farmacia, Università di Napoli Federico II, Via Domenico Montesano 49, 80131 Napoli, Italy.
| | - Ettore Novellino
- Dipartimento di Farmacia, Università di Napoli Federico II, Via Domenico Montesano 49, 80131 Napoli, Italy
| | - Federico Da Settimo
- Dipartimento di Farmacia, Università di Pisa, Via Bonanno Pisano 6, 56126 Pisa, Italy
| | - Claudia Martini
- Dipartimento di Farmacia, Università di Pisa, Via Bonanno Pisano 6, 56126 Pisa, Italy
| |
Collapse
|
11
|
Crespo A, El Maatougui A, Biagini P, Azuaje J, Coelho A, Brea J, Loza M, Cadavid MI, García-Mera X, Gutiérrez-de-Terán H, Sotelo E. Discovery of 3,4-Dihydropyrimidin-2(1H)-ones As a Novel Class of Potent and Selective A2B Adenosine Receptor Antagonists. ACS Med Chem Lett 2013; 4:1031-6. [PMID: 24900602 PMCID: PMC4027370 DOI: 10.1021/ml400185v] [Citation(s) in RCA: 47] [Impact Index Per Article: 4.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/14/2013] [Accepted: 10/03/2013] [Indexed: 01/18/2023] Open
Abstract
We describe the discovery and optimization of 3,4-dihydropyrimidin-2(1H)-ones as a novel family of (nonxanthine) A2B receptor antagonists that exhibit an unusually high selectivity profile. The Biginelli-based hit optimization process enabled a thoughtful exploration of the structure-activity and structure-selectivity relationships for this chemotype, enabling the identification of ligands that combine structural simplicity with excellent hA2B AdoR affinity and remarkable selectivity profiles.
Collapse
Affiliation(s)
- Abel Crespo
- Center for Research in Biological Chemistry and Molecular
Materials (CIQUS), Institute of Industrial Pharmacy, Department of Organic Chemistry, Faculty of
Pharmacy, University of Santiago de Compostela, Santiago de Compostela 15782, Spain
| | - Abdelaziz El Maatougui
- Center for Research in Biological Chemistry and Molecular
Materials (CIQUS), Institute of Industrial Pharmacy, Department of Organic Chemistry, Faculty of
Pharmacy, University of Santiago de Compostela, Santiago de Compostela 15782, Spain
| | - Pierfrancesco Biagini
- Center for Research in Biological Chemistry and Molecular
Materials (CIQUS), Institute of Industrial Pharmacy, Department of Organic Chemistry, Faculty of
Pharmacy, University of Santiago de Compostela, Santiago de Compostela 15782, Spain
| | - Jhonny Azuaje
- Center for Research in Biological Chemistry and Molecular
Materials (CIQUS), Institute of Industrial Pharmacy, Department of Organic Chemistry, Faculty of
Pharmacy, University of Santiago de Compostela, Santiago de Compostela 15782, Spain
| | - Alberto Coelho
- Center for Research in Biological Chemistry and Molecular
Materials (CIQUS), Institute of Industrial Pharmacy, Department of Organic Chemistry, Faculty of
Pharmacy, University of Santiago de Compostela, Santiago de Compostela 15782, Spain
| | - José Brea
- Center for Research in Biological Chemistry and Molecular
Materials (CIQUS), Institute of Industrial Pharmacy, Department of Organic Chemistry, Faculty of
Pharmacy, University of Santiago de Compostela, Santiago de Compostela 15782, Spain
| | - María
Isabel Loza
- Center for Research in Biological Chemistry and Molecular
Materials (CIQUS), Institute of Industrial Pharmacy, Department of Organic Chemistry, Faculty of
Pharmacy, University of Santiago de Compostela, Santiago de Compostela 15782, Spain
| | - María Isabel Cadavid
- Center for Research in Biological Chemistry and Molecular
Materials (CIQUS), Institute of Industrial Pharmacy, Department of Organic Chemistry, Faculty of
Pharmacy, University of Santiago de Compostela, Santiago de Compostela 15782, Spain
| | - Xerardo García-Mera
- Center for Research in Biological Chemistry and Molecular
Materials (CIQUS), Institute of Industrial Pharmacy, Department of Organic Chemistry, Faculty of
Pharmacy, University of Santiago de Compostela, Santiago de Compostela 15782, Spain
| | - Hugo Gutiérrez-de-Terán
- Department of Cell
and Molecular Biology, Uppsala University,
Biomedical Center, Uppsala SE-75124, Sweden
| | - Eddy Sotelo
- Center for Research in Biological Chemistry and Molecular
Materials (CIQUS), Institute of Industrial Pharmacy, Department of Organic Chemistry, Faculty of
Pharmacy, University of Santiago de Compostela, Santiago de Compostela 15782, Spain
| |
Collapse
|
12
|
Taliani S, Trincavelli ML, Cosimelli B, Laneri S, Severi E, Barresi E, Pugliesi I, Daniele S, Giacomelli C, Greco G, Novellino E, Martini C, Da Settimo F. Modulation of A2B adenosine receptor by 1-Benzyl-3-ketoindole derivatives. Eur J Med Chem 2013; 69:331-7. [PMID: 24077183 DOI: 10.1016/j.ejmech.2013.09.001] [Citation(s) in RCA: 23] [Impact Index Per Article: 2.1] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/03/2013] [Accepted: 09/02/2013] [Indexed: 11/17/2022]
Abstract
We have disclosed a series of 1-benzyl-3-ketoindole derivatives acting as either positive or negative modulators of the human A(2B) adenosine receptor (A(2B) AR) depending on small differences in their side chain. The new compounds were designed taking into account structural similarities between AR antagonists and ligands of the GABA(A)/benzodiazepine receptor. All compounds resulted totally inactive at A(2A) and A₃ ARs and showed small (8a,b) or none (7a,b, 8c and 9a,b) affinity for A₁ AR. When tested on A(2B) AR-transfected CHO cells, 7a,b and 8a acted as positive modulators, whereas 8b,c and 9a,b acted as negative modulators, enhancing or weakening the NECA-induced increase of cAMP levels, respectively. Compounds 7-9 might be regarded as useful biological and pharmacological tools to explore the therapeutic potential of A(2B) AR modulators, while their 3-ketoindole scaffold might be taken as a reference to design new analogs.
Collapse
Affiliation(s)
- Sabrina Taliani
- Dipartimento di Farmacia, Università di Pisa, Via Bonanno 6, 56126 Pisa, Italy
| | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
13
|
Affiliation(s)
- David J St Jean
- Department of Therapeutic Discovery, Amgen, Inc, Thousand Oaks, CA 91320, USA
| | | |
Collapse
|
14
|
Baraldi PG, Baraldi S, Saponaro G, Preti D, Romagnoli R, Piccagli L, Cavalli A, Recanatini M, Moorman AR, Zaid AN, Varani K, Borea PA, Tabrizi MA. Novel 1,3-dipropyl-8-(3-benzimidazol-2-yl-methoxy-1-methylpyrazol-5-yl)xanthines as potent and selective A₂B adenosine receptor antagonists. J Med Chem 2012; 55:797-811. [PMID: 22148859 DOI: 10.1021/jm201292w] [Citation(s) in RCA: 18] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/04/2023]
Abstract
Molecular modeling studies, including the comparative molecular field analysis (CoMFA) method, on 52 antagonists of the A(2B) adenosine receptor with known biological activity were performed to identify the three-dimensional features responsible for A(2B) adenosine receptor antagonist activity. On the basis of these and previous results on the potent antagonist effect of 8-pyrazolyl-xanthines at human A(2B)AR, a new series of compounds was synthesized and evaluated in binding studies against the human A(1), A(2A), A(3), and A(2B)ARs. A remarkable improvement in selectivity with respect to the previous series, maintaining the potency at human A(2B) receptor, was achieved, as exemplified by the 8-[3-(4-chloro-6-trifluoromethyl-1H-benzoimidazol-2-yl-methoxy)-1-methyl-1H-pyrazol-5-yl]-1,3-dipropyl-3,7-dihydro-purine-2,6-dione derivative 66: K(i) A(2B) = 9.4 nM, IC(50) hA(2B) = 26 nM hA(1)/hA(2B) = 269, hA(2A)/hA(2B) > 106, hA(3)/hA(2B) >106. This study also led to the identification of a series of pyrazole-xanthine compounds with a simplified structure, exemplified by 8-(3-hydroxy-1-methyl-1H-pyrazol-5-yl)-xanthine 80 displaying very high affinity at A(2B)AR with good selectivity over AR subtypes (K(i) = 4.0 nM, IC(50) hA(2B) = 20 nM hA(1)/hA(2B) = 183, hA(2A),hA(3)/hA(2B) > 250).
Collapse
Affiliation(s)
- Pier Giovanni Baraldi
- Department of Pharmaceutical Sciences, University of Ferrara, Via Fossato di Mortara 17-19, 44100 Ferrara, Italy.
| | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
15
|
Müller CE, Jacobson KA. Recent developments in adenosine receptor ligands and their potential as novel drugs. BIOCHIMICA ET BIOPHYSICA ACTA 2011; 1808:1290-308. [PMID: 21185259 PMCID: PMC3437328 DOI: 10.1016/j.bbamem.2010.12.017] [Citation(s) in RCA: 332] [Impact Index Per Article: 25.5] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Received: 07/12/2010] [Revised: 12/14/2010] [Accepted: 12/15/2010] [Indexed: 01/16/2023]
Abstract
Medicinal chemical approaches have been applied to all four of the adenosine receptor (AR) subtypes (A(1), A(2A), A(2B), and A(3)) to create selective agonists and antagonists for each. The most recent class of selective AR ligands to be reported is the class of A(2B)AR agonists. The availability of these selective ligands has facilitated research on therapeutic applications of modulating the ARs and in some cases has provided clinical candidates. Prodrug approaches have been developed which improve the bioavailability of the drugs, reduce side-effects, and/or may lead to site-selective effects. The A(2A) agonist regadenoson (Lexiscan®), a diagnostic drug for myocardial perfusion imaging, is the first selective AR agonist to be approved. Other selective agonists and antagonists are or were undergoing clinical trials for a broad range of indications, including capadenoson and tecadenoson (A(1) agonists) for atrial fibrillation, or paroxysmal supraventricular tachycardia, respectively, apadenoson and binodenoson (A(2A) agonists) for myocardial perfusion imaging, preladenant (A(2A) antagonist) for the treatment of Parkinson's disease, and CF101 and CF102 (A(3) agonists) for inflammatory diseases and cancer, respectively.
Collapse
|